Comprehensive Study Guide for Jascade and OFEV Package Inserts
Session Overview and Training Housekeeping
The session, designated as Vilt Number 3, is a comprehensive review of the Package Insert (PI) for Jascade and a summary of the OFEV PI.
The trainer, Amy, emphasizes that the entirety of the session contains "pearls" for the upcoming Jascade PI exam (scheduled for Tuesday) and the OFEV exam (scheduled for Wednesday).
Jascade Exam Details:
25 multiple-choice questions.
45-minute time limit.
Passing score requirement: .
Teach-back Presentations:
These should be no more than .
They involve using a few PowerPoint slides or props to teach a high-level concept to someone with no prior knowledge of the topic.
Students are encouraged to use the time after the Jascade exam to collaborate with partners on these presentations.
Technical Note: The trainer is working with the Viva team to resolve issues regarding missing accounts/providers in the IVA (Interactive Visual Aid) software.
Personal Narrative: Letter to My Lungs
Amy and a participant named Robin share personal stories as part of a "Letter to My Lungs" exercise to contextualize the respiratory space.
Amy’s Narrative:
Developed severe asthma at age three following a pony ride.
Inherited "dramatic lungs" from her father, who was relocated from Michigan to Arizona for the climate due to childhood asthma.
Experienced treatment with oxygen tents, nebulizers, epinephrine shots, and steroids (which she jokes affected her height).
Notes a singular event where a massive asthma attack kept her father home from a business trip on the night a drunk driver killed the four colleagues who went in his place.
Spent nearly working in the respiratory space to help others with lung issues.
Robin’s Narrative:
An ex-smoker who grew up in a culture where smoking was expected (New York).
Expresses gratitude to her lungs for "covering" for her despite years of smoking cigarettes and marijuana.
Highlights the importance of honesty regarding lifestyle choices in the context of respiratory health.
Historical Context of Lung Disease Treatments: OFEV and Esbriet
OFEV (Nintedanib):
Generic name: Nintedanib.
Mnemonic: "No PE" (No = Nintedanib = OFEV).
Launched in .
Three Indications:
IPF (Idiopathic Pulmonary Fibrosis).
SSC-ILD (Systemic Sclerosis-associated Interstitial Lung Disease).
Progressive Fibrosing ILD (formerly known as CF-ILD: Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype).
Principal side effect: Diarrhea (most severe in the first ).
Esbriet (Pirfenidone):
Generic name: Pirfenidone.
Mnemonic: "PE" (PE = Pirfenidone = Esbriet).
Launched in by Genentech.
Indications: Only one (IPF).
Principal side effect: Photosensitivity (a major concern in sunny climates like Arizona or Florida).
Generic Availability: Both Nintedanib and Pirfenidone are now available generically. Some insurance plans require a "step edit," where patients must fail one of these treatments before accessing Jascade.
Jascade (Nerandomolast) Indications and Administration
Generic Name: Nerandomolast.
Indications (Section 1.1 and 1.2):
Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Treatment of Progressive Pulmonary Fibrosis (PPF).
Dosing (Section 2.1, 2.2, 2.3):
Recommended maximum dosage: orally twice daily (, approximately apart).
Reduced dosage: twice daily if the patient is intolerant or if using specific concomitant medications.
Administration Options:
Swallowed Whole: Can be taken with or without food.
Water Dispersion Method: For patients with difficulty swallowing.
Place tablet in a glass with approximately () of room-temperature water.
Stir and let sit for until fully dispersed into small pieces.
Drink the mixture within of preparation.
Rinse the glass with an additional of water and drink immediately to ensure the full dose is consumed.
Missed Doses: If a dose is missed, patients should take the next dose at the scheduled time. They should not double the dose to make up for the missed one.
Dosage Forms (Section 3): Available as and tablets.
Warnings and Precautions: There are currently no warnings or precautions listed in the Jascade PI.
Jascade Drug Interactions and Special Populations
Pirfenidone (Esbriet) Interaction (Section 7.1):
Concomitant use with Pirfenidone decreases the exposure of Nerandomolast.
Required dose: Patients on Pirfenidone must take Jascade BID.
Important: Do not reduce the dosage to BID because efficacy was not observed at the lower dose when combined with Pirfenidone.
Strong CYP3A Inhibitors (Section 2.2 and 7.1):
Concomitant use with strong CYP3A inhibitors increases Nerandomolast exposure.
Recommended Action: Reduce Jascade dosage to twice daily.
Examples: Itraconazole (Sporanox), Ketoconazole, Ritonavir, Clarithromycin, and Grapefruit Juice.
Pregnancy (Section 8.1):
No available human data to evaluate drug-associated risks for birth defects or miscarriage.
Animal data exists, but the drug has not been studied in pregnant humans.
There are risks to both mother and fetus if conditions like IPF go untreated during pregnancy.
Hepatic Impairment (Section 8.7):
Child-Pugh Class A (Mild) and Class B (Moderate): No dosage adjustment required. Dosing remains the same as for patients with normal hepatic function.
Child-Pugh Class C (Severe): Not studied; use is likely avoided.
Safety Profile: The Diarrhea Theme
Adverse Reactions (Section 6.1):
The most frequent adverse reaction leading to treatment discontinuation was diarrhea.
FiberNeer IPF Study Discontinuation Rates:
Jascade BID (Without background anti-fibrotics): discontinuation due to diarrhea.
Jascade BID (Without background anti-fibrotics): discontinuation due to diarrhea.
Placebo (Without background anti-fibrotics): discontinuation due to diarrhea.
Contextual Comparison: While of all-comer patients reported diarrhea as an adverse event (often due to background treatment with Nintedanib), the actual discontinuation rate for Jascade alone is very low ().
Note on COVID-19: COVID-19 appears on the adverse reaction list in the PI. The drug does not cause COVID; rather, these events occurred and were reported during the global pandemic while the trials were active.
Mechanism of Action (MOA)
Classification (Section 12.1): Nerandomolast is an inhibitor of Phosphodiesterase 4 (PDE4).
Selectivity: It demonstrates at least a ninefold preferential inhibition of the PDE4B isoenzyme over PDE4A, C, and D based on in-vitro data.
Process:
PDE4 normally hydrolyzes and inactivates cyclic adenosine monophosphate (cAMP).
By inhibiting PDE4 (specifically the B isoenzyme found in the lungs and CNS), Jascade elevates cellular levels.
This reduction in hydrolysis leads to reduced expression of pro-fibrotic growth factors and inflammatory cytokines.
Effects: Exerts both anti-fibrotic and immunomodulatory effects.
Clinical Significance: Targeting the PDE4B isoenzyme specifically (the "ninefold preference") rather than being a "pan-PDE4" inhibitor helps reduce the physiological "baggage" or side effects typically associated with this drug class (e.g., severe nausea or diarrhea).
Clinical Trials: FiberNeer IPF
Primary Endpoint: Absolute change from baseline in Forced Vital Capacity (FVC) in milliliters () at .
Secondary Endpoint: A composite endpoint consisting of the time to the first occurrence of:
Acute IPF exacerbation.
First hospitalization for respiratory cause.
Death.
Numerical Results at 52 Weeks (Adjusted Mean Decline in FVC):
Jascade : .
Jascade : .
Placebo Group: .
Clinical Trials: FiberNeer ILD (Progressive Pulmonary Fibrosis)
Trial Population: of patients were on stable background treatment with Nintedanib (OFEV); were not on Nintedanib.
Definition of Progression (Section 14.2): Patients must have presented with at least two of the following clinical signs within the prior to screening:
FVC decline .
FVC decline and with worsening of respiratory symptoms or imaging.
Worsening of respiratory symptoms and worsening of imaging.
Numerical Results at 52 Weeks (Adjusted Mean Decline in FVC):
Jascade : .
Jascade : .
Placebo Group: .
Secondary Endpoint: Time to first occurrence of a composite of acute ILD exacerbation, respiratory-cause hospitalization, or death over the blinded duration (up to ).
Questions & Discussion
Question (Chris): Will the exam require knowing the specific page numbers or paragraph locations?
Response (Amy): No, the exam focuses on identifying the information itself, not the physical location in the document.
Question (Chris): What is the significance of the ninefold preferential inhibition of PDE4B?
Response (Amy): It means the drug is much more specific to inhibiting the B isoenzyme (located in the lungs) rather than A, C, or D. This specificity is why we see improved tolerability and lower rates of gastrointestinal side effects compared to non-selective PDE4 inhibitors.
Question (Lisa): Does the dosing change for liver function?
Response (Amy): No adjustment is needed for mild or moderate (Child-Pugh A or B) impairment. Severe (Class C) has not been studied.
Question (Chris): What is the half-life of Jascade?
Response (Amy): Amy initially notes that this is rarely discussed in the field but finds that it takes four days to reach a steady state. She clarifies for OFEV that the half-life is approximately . (Note: She pledges to double-check the exact Jascade half-life for the group).
Question (Reagan): Are numerical values required for the primary/secondary endpoints?
Response (Amy): You need to know what the endpoints are (e.g., absolute change in FVC) and the key result numbers from the trials (e.g., vs. ).